PROGNOSIS-RELATED NOVEL IMMUNOSTAINING PATTERN FOR PROGRAMMED CELL DEATH LIGAND 1 AND PROGNOSTIC VALUE OF TUMOUR-INFILTRATING LYMPHOCYTES IN TRIPLE-NEGATIVE BREAST CANCER

被引:0
作者
Savas, Pinar [1 ]
Serin, Gurdeniz [1 ]
Gursoy, Pinar [2 ]
Zekioglu, Osman [1 ]
Ozdemir, Necmettin [1 ]
机构
[1] Ege Univ, Sch Med, Dept Pathol, Izmir, Turkiye
[2] Ege Univ, Tulay Aktas Oncol Hosp, Sch Med, Izmir, Turkiye
关键词
immune checkpoint blockade; programmed cell death 1; programmed cell death ligand 1; triple-negative breast cancer; tumour-infiltrating lymphocyte; PD-L1; EXPRESSION; POOR-PROGNOSIS;
D O I
10.5114/PJP.2023.129014
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This study aims to determine the prognostic significance of programmed cell death ligand 1 (PD-L1) expression and tumour-infiltrating lymphocytes (TILs) in triple negative breast cancer (TNBC).PD-L1 expression and TIL percentage were determined in TNBCs that did not receive neoadjuvant therapy. The relationship between PD-L1 expression and the percentage of TILs with survival was investigated.The presence of intratumoural PD-L1-positive tumour-infiltrating immune cells (TIICs) in tumours with >= 1% PD-L1 expression was identified as a new PD-L1 evaluation parameter. The presence of intratumoural PD-L1-positive TIICs as a new parameter in PD-L1-positive cases increased overall survival. The percentage of TILs increased in both overall and distant metastasis-free survival (p = 0.040 and p = 0.006, respectively). As a result, it was found that the risk of death was increased 5.18-fold (p = 0.013) in patients without intratumoural PD-L1-positive TIICs. This risk of death was calculated to be 5.40-fold higher in patients with TIL percentage <= 10% than in those with > 40% (p = 0.024), and the risk of distant metastasis was calculated to be 11.95 times higher.In our study, we discovered that the percentage of TILs made a statistically significant difference in TNBC survival. The presence of intratumoural PD-L1-positive TIICs in PD-L1-positive cases significantly increased survival.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 30 条
[1]   Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].
Adams, Sylvia ;
Diamond, Jennifer R. ;
Hamilton, Erika ;
Pohlmann, Paula R. ;
Tolaney, Sara M. ;
Chang, Ching-Wei ;
Zhang, Wei ;
Iizuka, Koho ;
Foster, Paul G. ;
Molinero, Luciana ;
Funke, Roel ;
Powderly, John .
JAMA ONCOLOGY, 2019, 5 (03) :334-342
[2]   Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].
Adams, Sylvia ;
Gray, Robert J. ;
Demaria, Sandra ;
Goldstein, Lori ;
Perez, Edith A. ;
Shulman, Lawrence N. ;
Martino, Silvana ;
Wang, Molin ;
Jones, Vicky E. ;
Saphner, Thomas J. ;
Wolff, Antonio C. ;
Wood, William C. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Sparano, Joseph A. ;
Badve, Sunil S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+
[3]   PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes [J].
Ali, H. R. ;
Glont, S. -E. ;
Blows, F. M. ;
Provenzano, E. ;
Dawson, S. -J. ;
Liu, B. ;
Hiller, L. ;
Dunn, J. ;
Poole, C. J. ;
Bowden, S. ;
Earl, H. M. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2015, 26 (07) :1488-1493
[4]   Prognostic significance of PD-L1 and PD-L2 in breast cancer [J].
Baptista, Mauricio Z. ;
Sarian, Luis Otavio ;
Derchain, Sophie F. M. ;
Pinto, Glauce A. ;
Vassal, Jose .
HUMAN PATHOLOGY, 2016, 47 (01) :78-84
[5]   Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome [J].
Beckers, Rhiannon K. ;
Selinger, Christina I. ;
Vilain, Ricardo ;
Madore, Jason ;
Wilmott, James S. ;
Harvey, Kate ;
Holliday, Anne ;
Cooper, Caroline L. ;
Robbins, Elizabeth ;
Gillett, David ;
Kennedy, Catherine W. ;
Gluch, Laurence ;
Carmalt, Hugh ;
Mak, Cindy ;
Warrier, Sanjay ;
Gee, Harriet E. ;
Chan, Charles ;
McLean, Anna ;
Walker, Emily ;
McNeil, Catriona M. ;
Beith, Jane M. ;
Swarbrick, Alexander ;
Scolyer, Richard A. ;
O'Toole, Sandra A. .
HISTOPATHOLOGY, 2016, 69 (01) :25-34
[6]   Immunotherapy of Breast Cancer [J].
Criscitiello, Carmen ;
Curigliano, Giuseppe .
IMMUNO-ONCOLOGY, 2015, 42 :30-43
[7]   Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study [J].
Emens, Leisha A. ;
Cruz, Cristina ;
Eder, Joseph Paul ;
Braiteh, Fadi ;
Chung, Cathie ;
Tolaney, Sara M. ;
Kuter, Irene ;
Nanda, Rita ;
Cassier, Philippe A. ;
Delord, Jean-Pierre ;
Gordon, Michael S. ;
ElGabry, Ehab ;
Chang, Ching-Wei ;
Sarkar, Indrani ;
Grossman, William ;
O'Hear, Carol ;
Fasso, Marcella ;
Molinero, Luciana ;
Schmid, Peter .
JAMA ONCOLOGY, 2019, 5 (01) :74-82
[8]   Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type [J].
Gatalica, Zoran ;
Snyder, Carrie ;
Maney, Todd ;
Ghazalpour, Anatole ;
Holterman, Daniel A. ;
Xiao, Nianqing ;
Overberg, Peggy ;
Rose, Inga ;
Basu, Gargi D. ;
Vranic, Semir ;
Lynch, Henry T. ;
Von Hoff, Daniel D. ;
Hamid, Omid .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (12) :2965-2970
[9]   The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice [J].
Gonzalez-Ericsson, Paula, I ;
Stovgaard, Elisabeth S. ;
Sua, Luz F. ;
Reisenbichler, Emily ;
Kos, Zuzana ;
Carter, Jodi M. ;
Michiels, Stefan ;
Le Quesne, John ;
Nielsen, Torsten O. ;
Laenkholm, Anne-Vibeke ;
Fox, Stephen B. ;
Adam, Julien ;
Bartlett, John M. S. ;
Rimm, David L. ;
Quinn, Cecily ;
Peeters, Dieter ;
Dieci, Maria, V ;
Vincent-Salomon, Anne ;
Cree, Ian ;
Hida, Akira, I ;
Balko, Justin M. ;
Haynes, Harry R. ;
Frahm, Isabel ;
Acosta-Haab, Gabriela ;
Balancin, Marcelo ;
Bellolio, Enrique ;
Yang, Wentao ;
Kirtani, Pawan ;
Sugie, Tomoharu ;
Ehinger, Anna ;
Castaneda, Carlos A. ;
Kok, Marleen ;
McArthur, Heather ;
Siziopikou, Kalliopi ;
Badve, Sunil ;
Fineberg, Susan ;
Gown, Allen ;
Viale, Giuseppe ;
Schnitt, Stuart J. ;
Pruneri, Giancarlo ;
Penault-Llorca, Frederique ;
Hewitt, Stephen ;
Thompson, E. Aubrey ;
Allison, Kimberly H. ;
Symmans, William F. ;
Bellizzi, Andrew M. ;
Brogi, Edi ;
Moore, David A. ;
Larsimont, Denis ;
Dillon, Deborah A. .
JOURNAL OF PATHOLOGY, 2020, 250 (05) :667-684
[10]   Programmed cell death-1 inhibition in lymphoma [J].
Hawkes, Eliza A. ;
Grigg, Andrew ;
Chong, Geoff .
LANCET ONCOLOGY, 2015, 16 (05) :E234-E245